GDS

About This Project

With nearly 15% of the current population over 18 years old obese, obesity is on the verge of becoming a global pandemic. Obesity can lead to serious health issues, like diabetes, coronary heart diseases and several types of cancers. Each year obesity related conditions cost globally over €1.7 trillion and cause almost 2.8 million deaths. It is estimated that the EU spends almost 7% of their GDP in obesity treatments. The current gold standard for weight loss Roux-en-Y Gastric Bypass (RYGB) is effective, but extremely expensive, surgically invasive and has life-threating side-effects.

 

The GDS is an innovative non-surgical procedure for weight loss, that is reversible, it is 7 times cheaper than RYGB, and can be done in 30 minutes without hospitalization time or the need of a big surgical team. The GDS is composed of a polymeric flexible sleeve inserted in the duodenum with a patented anchoring system to stop the sleeve from migrating to the small intestine. The sleeve prevents weight gain through malabsorption of calories and the anchor increases the satiety sensation in the user.

Topic
PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Year

2018

Cutoff

February

Beneficiaries

Coordinator

Allevetix Medical Ltd

Country

Israel

Website

Link